Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

Innovative approach using KITE-439 in targeting HPV-related malignancies

August 20, 2019 | City of Hope

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.

PSCA as a novel CAR T target for resistant prostate cancer

August 20, 2019 | City of Hope

In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.

City of Hope scientist receives $9.28M for CAR T trial for metastatic breast cancer

August 15, 2019 | Letisia Marquez

Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

Caitlin's journey: Lymphoma patient gets fresh start with CAR T

July 31, 2019 | Abe Rosenberg

Diagnosed with a rare, fast-growing blood cancer and ineligible for a lifesaving stem cell transplant after failing chemotherapy, treatment with a breakthrough CAR T drug called Yescarta was Caitlin Buchanan's best hope for survival.

ASCO research highlights: First KRAS inhibitor and CAR T cell therapy for CLL

June 28, 2019 | City of Hope

At ASCO, City of Hope presented on a number of topics, but some of the most noteworthy involved the first KRAS inhibitor to show anti-tumor activity and the use of CAR T cell therapy in chronic lymphocytic leukemia.

Survivor Month: A second chance, thanks to CAR T trial

June 27, 2019 | Dory Benford

Tyler Routh is one of 13 leukemia patients who had a remarkable recovery after participating in Dr. Samer Khaled’s CAR T trial.